UBX1325

DRUG2 trials

Sponsors

Unity Biotechnology, Inc.

Conditions

Diabetic Macular EdemaDiabetic Macular Edema (DME)Neovascular Age-related Macular Degeneration

Phase 1

Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration

CompletedNCT04537884

Unity Biotechnology, Inc.Diabetic Macular Edema, Neovascular Age-related Macular Degeneration

Start: 2020-10-08End: 2022-01-25Updated: 2022-03-10

Phase 2

Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)

CompletedNCT04857996

Unity Biotechnology, Inc.Diabetic Macular Edema (DME)

Start: 2021-06-25End: 2023-04-06Updated: 2024-05-16

Related Papers

Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema

NEJM Evidence2025-04-227 citations

Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results.

2024-02-0660 citations